肉毒毒素注射在痉挛型脑瘫儿童综合康复前的成本效果研究
这项实用设计的多中心试验纳入65例4-12岁、GMFCS I-III级的痉挛型脑瘫步行儿童,比较A型肉毒毒素+强化物理治疗与单纯强化物理治疗的效果与成本。主要终点12周时仅发现单纯强化物理治疗组在客观测量的久坐行为百分比上略优,肉毒毒素组治疗成本显著更高(8,963 vs 6,182欧元,p=0.001),24周随访两组无显著差异。结论认为加用A型肉毒毒素未改善康复效果且不具成本效果。
要点
- 4-12岁GMFCS I-III级痉挛型脑瘫步行儿童中,肉毒毒素+强化物理治疗未优于单纯强化物理治疗。
- 12周时仅久坐行为百分比在单纯强化物理治疗组略优,其余主要结局无显著差异。
- 肉毒毒素组治疗成本显著更高(8,963 vs 6,182欧元,p=0.001),不具成本效果。
核心结论
- 在4-12岁GMFCS I-III级痉挛型脑瘫步行儿童中,强化物理治疗前加用A型肉毒毒素未改善粗大运动功能、活动水平或健康相关生活质量,且不具成本效果。
研究设计与样本
- 实用设计的多中心试验,比较A型肉毒毒素+强化物理治疗与单纯强化物理治疗,并包含经济评价。
- 共纳入65例痉挛型脑瘫儿童(37例男性),平均年龄7.3岁(标准差2.3岁),GMFCS I-III级分布均匀。
- 主要结局在基线、12周(主要终点)和24周(随访)评估,采用意向性分析及线性混合模型。
主要发现
- 12周主要终点时,仅客观测量的久坐行为百分比在单纯强化物理治疗组更优(-3.42,95%CI 0.20-6.64,p=0.038)。
- A型肉毒毒素+强化物理治疗组的治疗成本显著更高(8,963 vs 6,182欧元,p=0.001)。
- 24周随访时两组间未发现统计学显著差异。
关键数值与推荐
- 主要结局包括粗大运动功能、身体活动水平和健康相关生活质量。
- 经济结局包括医疗成本和患者成本。
- 久坐行为百分比差异为-3.42(95%CI 0.20-6.64,p=0.038),利于单纯强化物理治疗组。
- 治疗成本差异为8,963 vs 6,182欧元(p=0.001),肉毒毒素组更高。
临床怎么用
- 对于4-12岁GMFCS I-III级痉挛型脑瘫步行儿童,不建议常规在强化物理治疗前加用A型肉毒毒素以改善粗大运动功能、活动水平或健康相关生活质量。
- 在考虑肉毒毒素注射时,应结合成本效果信息与个体化康复目标进行决策。
局限性
- 研究仅针对4-12岁GMFCS I-III级步行儿童,结论不能外推至其他年龄或严重程度亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite the widespread use of botulinum toxin in ambulatory children with spastic cerebral palsy, its value prior to intensive physiotherapy with adjunctive casting/orthoses remains unclear. DESIGN: A pragmatically designed, multi-centre trial, comparing the effectiveness of botulinum toxin + intensive physiotherapy with intensive physiotherapy alone, including economic evaluation. SUBJECTS/PATIENTS: Children with spastic cerebral palsy, age range 4-12 years, cerebral palsy-severity Gross Motor Function Classification System levels I-III, received either botulinum toxin type A + intensive physiotherapy or intensive physiotherapy alone and, if necessary, ankle-foot orthoses and/or casting. METHODS: Primary outcomes were gross motor func-tion, physical activity levels, and health-related quality-of-life, assessed at baseline, 12 (primary end-point) and 24 weeks (follow-up). Economic outcomes included healthcare and patient costs. Intention-to-treat analyses were performed with linear mixed models. RESULTS: There were 65 participants (37 males), with a mean age of 7.3 years (standard deviation 2.3 years), equally distributed across Gross Motor Function Classification System levels. Forty-one children received botulinum toxin type A plus intensive physio-therapy and 24 received intensive physiotherapy treatment only. At primary end-point, one statistically significant difference was found in favour of intensive physiotherapy alone: objectively measured percentage of sedentary behaviour (-3.42, 95% confidence interval 0.20-6.64, p=0.038). Treatment costs were significantly higher for botulinum toxin type A plus intensive physiotherapy (8,963 vs 6,182 euro, p=0.001). No statistically significant differences were found between groups at follow-up. CONCLUSION: The addition of botulinum toxin type A to intensive physiotherapy did not improve the effectiveness of rehabilitation for ambulatory children with spastic cerebral palsy and was also not cost-effective. Thus botulinum toxin is not recommended for use in improving gross motor function, activity levels or health-related quality-of-life in this cerebral palsy age- and severity-subgroup.
引用
- Schasfoort F, Dallmeijer A, Pangalila R, et al. Value of botulinum toxin injections preceding a comprehensive rehabilitation period for children with spastic cerebral palsy: A cost-effectiveness study. J Rehabil Med. 2018. PMID: 28949368. doi:10.2340/16501977-2267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。